{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:47:26Z","timestamp":1792547246668,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synovial sarcoma (SS) is one of the commonest non-rhabdomyosarcoma soft tissue sarcoma with limited treatment options in the relapsed and advanced settings. The combination of gemcitabine and docetaxel has demonstrated its role predominantly in leiomyosarcoma and pleomorphic sarcomas but has not been prospectively studied in SS. This trial assesses the efficacy, tolerability and quality of life (QoL) with this regimen in metastatic\/unresectable locally advanced relapsed SS.<\/jats:p><jats:p><jats:bold>Patients and methods<\/jats:bold> This was a single-arm, two-stage, phase II, investigator-initiated interventional study among patients with metastatic or unresectable locally advanced SS who had progressed after at least one line of chemotherapy. Gemcitabine 900\u00a0mg\/m2 on days 1 and 8 and docetaxel 75\u00a0mg\/m2 on day 8 were administered intravenously every 21\u00a0days. The primary endpoint was 3-month progression-free rate (PFR); overall survival (OS), progression-free survival (PFS), overall response rate (ORR), safety and quality of life (QoL) constituted the secondary endpoints.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> Twenty-two patients were enrolled between March 2020 and September 2021 and the study had to be closed early due to slow accrual. The study population comprised of 18 (81.8%) patients with metastatic disease and 4 (18.2%) patients with locally advanced, unresectable disease. The most common primary sites of disease were extremity in 15 (68%) and the median number of lines of prior therapies received was 1 (range 1\u20134). 3-month PFR was 45.4% (95% CI 24.8\u201366.1) and ORR was 4.5%. Median progression-free survival (PFS) was 3\u00a0months (95% CI 2.3\u20133.6) and median OS was 14\u00a0months (95% CI 8.9\u201319.0). 7 (31.8%) patients experienced grade 3 or worse toxicities, including anemia (18%), neutropenia (9%) and mucositis (9%). QoL analysis demonstrated significant decline in certain functional and symptom scales, while financial and global health scales remained stable.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> This is the first prospective study on the combination of gemcitabine and docetaxel performed specifically in patients with advanced, relapsed SS. Although the accrual of patients could not be completed as planned, the therapy did produce clinically meaningful outcomes and met its primary endpoint of 3-month PFR. This result, along with the manageable toxicity profile and stable global health status on QoL analysis, should encourage further studies.<\/jats:p><jats:p><jats:bold>Trial registration<\/jats:bold> This trial was prospectively registered under the Clinical Trials Registry of India on 26\/02\/2020 (Registration number: CTRI\/2020\/02\/023612).<\/jats:p>","DOI":"10.1186\/s12885-023-11099-4","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T08:01:42Z","timestamp":1688803302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Ghazal","family":"Tansir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-3083","authenticated-orcid":false,"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Barwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asit R.","family":"Mridha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim A.","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Bhoriwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"issue":"6","key":"11099_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.6004\/jnccn.2010.0049","volume":"8","author":"GD Demetri","year":"2010","unstructured":"Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, et al. Soft tissue sarcoma. J Natl Compr Canc Netw. 2010;8(6):630\u201374.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"11099_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13566-012-0081-4","volume":"2","author":"BR Mancini","year":"2013","unstructured":"Mancini BR, Roberts KB. Pediatric non-rhabdomyosarcoma soft tissue sarcomas. J Radiat Oncol. 2013;2(2):135\u201348.","journal-title":"J Radiat Oncol"},{"key":"11099_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4103\/0019-509X.197734","volume":"53","author":"A Gulia","year":"2016","unstructured":"Gulia A, Puri A, Chorge S, Panda PK. Epidemiological data and case load spectrum of patients presenting to bone and soft tissue disease management group at a tertiary cancer center. Indian J Cancer. 2016;53:333\u20138.","journal-title":"Indian J Cancer"},{"issue":"11","key":"11099_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/cancers10110417","volume":"10","author":"RF Riedel","year":"2018","unstructured":"Riedel RF, Jones RL, Italiano A, Bohac C, Thompson JC, Mueller K, et al. Systemic anti-cancer therapy in synovial sarcoma: a systematic review. Cancers (Basel). 2018;10(11):417.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11099_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","volume":"15","author":"M Savina","year":"2017","unstructured":"Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15(1):78.","journal-title":"BMC Med"},{"issue":"13","key":"11099_CR6","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1002\/cncr.24370","volume":"115","author":"E Palmerini","year":"2009","unstructured":"Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, et al. Synovial sarcoma: a retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988\u201398.","journal-title":"Cancer"},{"issue":"1","key":"11099_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"S Sleijfer","year":"2010","unstructured":"Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first -line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72\u201383.","journal-title":"Eur J Cancer"},{"issue":"6","key":"11099_CR8","doi-asserted-by":"publisher","first-page":"e002072","DOI":"10.1136\/jitc-2020-002072","volume":"9","author":"G Mitchell","year":"2021","unstructured":"Mitchell G, Pollack SM, Wagner MJ. Targeting cancer testis antigens in synovial sarcoma. J Immunother Cancer. 2021;9(6):e002072.","journal-title":"J Immunother Cancer"},{"issue":"20","key":"11099_CR9","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1158\/1078-0432.CCR-20-0832","volume":"26","author":"E Rosenbaum","year":"2020","unstructured":"Rosenbaum E, Seier K, Bandlamudi C, Dickson M, Gounder M, Keohan ML, et al. HLA Genotyping in synovial sarcoma: identifying HLA-A*02 and its association with clinical outcome. Clin Cancer Res. 2020;26(20):5448.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"11099_CR10","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO.2004.08.043","volume":"22","author":"KM Leu","year":"2004","unstructured":"Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22(9):1706\u201312.","journal-title":"J Clin Oncol"},{"issue":"12","key":"11099_CR11","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","volume":"20","author":"ML Hensley","year":"2002","unstructured":"Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial. J Clin Oncol. 2002;20(12):2824\u201331.","journal-title":"J Clin Oncol"},{"key":"11099_CR12","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","volume":"21","author":"M Tempero","year":"2003","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"11099_CR13","first-page":"2650","volume":"41","author":"PM Colangelo","year":"1984","unstructured":"Colangelo PM, Welch DW, Rich DS, Jeffrey LP. Two methods for estimating body surface area in adult amputees. Am J hosp Pharm. 1984;41(12):2650\u20135.","journal-title":"Am J hosp Pharm"},{"issue":"2","key":"11099_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"5","key":"11099_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J. Natl Cancer Inst"},{"issue":"5","key":"11099_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s11136-014-0853-y","volume":"24","author":"CF Snyder","year":"2015","unstructured":"Snyder CF, Blackford AL, Sussman J, Bainbridge D, Howell D, Seow HY, et al. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients\u2019 supportive care needs. Qual Life Res. 2015;24(5):1207\u201316.","journal-title":"Qual Life Res"},{"issue":"4","key":"11099_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","volume":"38","author":"MV Glabbeke","year":"2002","unstructured":"Glabbeke MV, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38(4):543\u20139.","journal-title":"Eur J Cancer"},{"issue":"19","key":"11099_CR18","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol. 2007;25(19):2755\u201363.","journal-title":"J Clin Oncol"},{"issue":"10","key":"11099_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397\u2013410.","journal-title":"Lancet Oncol"},{"issue":"10","key":"11099_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12032-018-1193-5","volume":"35","author":"A Pender","year":"2018","unstructured":"Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, et al. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018;35(10):131.","journal-title":"Med Oncol"},{"issue":"1","key":"11099_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0959-8049(99)00240-3","volume":"36","author":"OS Nielsen","year":"2000","unstructured":"Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomasm A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36(1):61\u20137.","journal-title":"Eur J Cancer"},{"key":"11099_CR22","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1002\/cncr.29426","volume":"121","author":"C Coens","year":"2015","unstructured":"Coens C, van der Graaf WTA, Blay JY, Chawla SP, Judson I, Sanfilippo R, et al. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy\u2014a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072. Cancer. 2015;121:2933\u201341.","journal-title":"Cancer"},{"issue":"4","key":"11099_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Sch\u00f6ffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415\u201323.","journal-title":"Lancet Oncol"},{"issue":"12","key":"11099_CR24","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/bjc.1998.735","volume":"78","author":"OS Nielsen","year":"1998","unstructured":"Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, et al. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer. 1998;78(12):1634\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"11099_CR25","first-page":"543","volume":"35","author":"R De Sanctis","year":"2015","unstructured":"De Sanctis R, Bertuzzi A, Basso U, Comandone A, Marchetti S, Marrari A, et al. Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. Anticancer Res. 2015;35(1):543\u20137.","journal-title":"Anticancer Res"},{"issue":"15_suppl","key":"11099_CR26","doi-asserted-by":"publisher","first-page":"10044","DOI":"10.1200\/jco.2012.30.15_suppl.10044","volume":"30","author":"AS Rahal","year":"2012","unstructured":"Rahal AS, Cioffi A, Rahal C, Domont J, Blesius A, Patrikidou A, et al. High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience. J Clin Oncol. 2012;30(15_suppl):10044\u201310044.","journal-title":"J Clin Oncol"},{"issue":"8","key":"11099_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1634\/theoncologist.2016-0064","volume":"22","author":"M Takahashi","year":"2017","unstructured":"Takahashi M, Takahashi S, Araki N, Sugiura H, Ueda T, Yonemoto T, et al. Efficacy of trabectedin in patients with advanced translocation-related sarcomas: pooled analysis of two phase II Studies. Oncologist. 2017;22(8):979\u201388.","journal-title":"Oncologist"},{"issue":"6","key":"11099_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/CAD.0000000000000228","volume":"26","author":"R Sanfilippo","year":"2015","unstructured":"Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, et al. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015;26(6):678\u201381.","journal-title":"Anticancer Drugs"},{"issue":"19","key":"11099_CR29","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Sch\u00f6ffski P, et al. Pazopanib, a Multikinase Angiogenesis Inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer\u2013soft tissue and bone sarcoma group (EORTC Study 62043). J Clin Oncol. 2009;27(19):3126\u201332.","journal-title":"J Clin Oncol"},{"issue":"9829","key":"11099_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"12","key":"11099_CR31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2016;17(12):1732\u201342.","journal-title":"Lancet"},{"issue":"19","key":"11099_CR32","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","volume":"27","author":"RG Maki","year":"2009","unstructured":"Maki RG, D\u2019Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas. J Clin Oncol. 2009;27(19):3133\u201340.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"11099_CR33","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1200\/JCO.2021.39.15_suppl.11505","volume":"39","author":"BA Van Tine","year":"2021","unstructured":"Van Tine BA, Chawla SP, Trent JC, Wilky BA, Chugh R, Chmielowski B, et al. A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. J Clin Oncol. 2021;39(15_suppl):11505\u201311505.","journal-title":"J Clin Oncol"},{"issue":"8","key":"11099_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016;34(8):786\u201393.","journal-title":"J Clin Oncol"},{"issue":"32","key":"11099_CR35","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2217\/fon-2022-0348","volume":"18","author":"C Carroll","year":"2022","unstructured":"Carroll C, Patel N, Gunsoy NB, Stirnadel-Farrant HA, Pokras S. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). Future Oncol. 2022;18(32):3651\u201365.","journal-title":"Future Oncol"},{"issue":"15","key":"11099_CR36","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1200\/JCO.2017.35.15_suppl.11057","volume":"35","author":"P Schoffski","year":"2017","unstructured":"Schoffski P, Agulnik M, Stacchiotti S, Davis LE, Villalobos VM, Italiano A, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950). J Clin Oncol. 2017;35(15):11057\u201311057.","journal-title":"J Clin Oncol"},{"issue":"8","key":"11099_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discov. 2018;8(8):944\u201357.","journal-title":"Cancer Discov"},{"issue":"suppl_5","key":"11099_CR38","first-page":"v683","volume":"30","author":"BA Van Tine","year":"2020","unstructured":"Van Tine BA, Hong DS, Johnson ML. Durable responses in patients with synovial sarcoma in the phase I trial of ADP-A2M4 (MAGE-A4). Ann Oncol. 2020;30(suppl_5):v683\u2013709.","journal-title":"Ann Oncol"},{"issue":"9","key":"11099_CR39","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0198-8859(01)00298-1","volume":"62","author":"K Cao","year":"2001","unstructured":"Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fern\u00e1ndez-Vi\u00f1a MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62(9):1009\u201330.","journal-title":"Hum Immunol"},{"issue":"15_suppl","key":"11099_CR40","doi-asserted-by":"publisher","first-page":"11517","DOI":"10.1200\/JCO.2021.39.15_suppl.11517","volume":"39","author":"S Attia","year":"2021","unstructured":"Attia S, Villalobos VM, Hindi N, Van Tine BA, Wagner AJ, Chmielowski B, et al. Phase (Ph) 1b\/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS). J Clin Oncol. 2021;39(15_suppl):11517\u201311517.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11099-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11099-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11099-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T08:02:19Z","timestamp":1688803339000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11099-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11099"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11099-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,8]]},"assertion":[{"value":"23 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board, Institute Ethics Committee \u2013 All India Institute of Medical Sciences, Delhi (Reference number IECPG-719\/19). Furthermore, written informed consent was taken from all the participants and legal guardians (in case of patients aged less than 18\u00a0years).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"639"}}